MACROH2A1: A Potential Drug Target and Biomarker for Diseases

Target Name: MACROH2A1

NCBI ID: G9555

MACROH2A1

MACROH2A1: A Potential Drug Target and Biomarker for Diseases

MACROH2A1 (H2AY_HUMAN), a gene located on chromosome 6, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

MACROH2A1 is a gene that encodes a protein known as H2A.1, which is a key regulator of the microtubules in cells. Microtubules are dynamic structures that play a crucial role in cell division, transport, and signaling. Mammalian H2A.1 has been shown to play a role in regulating mitosis, cell division, and the distribution of organelles in the cell.

Studies have suggested that disruptions in MACROH2A1 gene function may contribute to the development and progression of various diseases. For example, MACROH2A1 has been shown to be downregulated in various types of cancer, including breast, ovarian, and prostate cancers. This downregulation has been associated with the development of cancer stem cells, which are cells that are capable of self-replication and have the potential to give rise to tumors.

In addition to its role in cancer, MACROH2A1 has also been implicated in a number of other diseases, including neurodegenerative disorders and autoimmune diseases. For example, MACROH2A1 has been shown to be downregulated in the brains of individuals with Alzheimer's disease, a neurodegenerative disorder. This downregulation has been associated with the loss of microtubules, which are thought to play a role in the regulation of neurotransmitter release and the maintenance of the integrity of the blood-brain barrier.

MACROH2A1 has also been implicated in the development and progression of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. In these diseases, the immune system attacks the body's own tissues, leading to inflammation and damage. MACROH2A1 has been shown to be involved in the regulation of immune cell function, suggesting that it may play a role in the development and progression of autoimmune diseases.

Despite these promising findings, more research is needed to fully understand the role of MACROH2A1 in disease. One approach to studying MACROH2A1 is to use RNA interference techniques to knockdown the expression of the gene in laboratory samples, and to assess the impact on cellular processes such as mitosis, cell division, and the distribution of organelles. This can help to determine whether disruptions in MACROH2A1 gene function contribute to the development and progression of various diseases.

Another approach to studying MACROH2A1 is to use techniques such as mass spectrometry to identify potential drug targets. This can help to identify small molecules that can interact with the protein and potentially lead to the inhibition of MACROH2A1 function.

Overall, MACROH2A1 is a gene that has the potential to be a drug target and biomarker for a variety of diseases. Further research is needed to fully understand the role of MACROH2A1 in disease, and to develop effective therapies that target this protein.

Protein Name: MacroH2A.1 Histone

Functions: Variant histone H2A which replaces conventional H2A in a subset of nucleosomes where it represses transcription (PubMed:12718888, PubMed:15621527, PubMed:16428466). Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template (PubMed:15897469). Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability (PubMed:15897469). DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. Involved in stable X chromosome inactivation (PubMed:15897469). Inhibits the binding of transcription factors, including NF-kappa-B, and interferes with the activity of remodeling SWI/SNF complexes (PubMed:12718888, PubMed:16428466). Inhibits histone acetylation by EP300 and recruits class I HDACs, which induces a hypoacetylated state of chromatin (PubMed:16428466, PubMed:16107708)

The "MACROH2A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MACROH2A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets